Repligen (RGEN) Competitors $118.91 +1.84 (+1.57%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$118.84 -0.06 (-0.05%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RGEN vs. TECH, A, DHR, TMO, BIIB, UTHR, NBIX, INCY, EXEL, and BMRNShould you be buying Repligen stock or one of its competitors? The main competitors of Repligen include Bio-Techne (TECH), Agilent Technologies (A), Danaher (DHR), Thermo Fisher Scientific (TMO), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), Exelixis (EXEL), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "medical" sector. Repligen vs. Its Competitors Bio-Techne Agilent Technologies Danaher Thermo Fisher Scientific Biogen United Therapeutics Neurocrine Biosciences Incyte Exelixis BioMarin Pharmaceutical Repligen (NASDAQ:RGEN) and Bio-Techne (NASDAQ:TECH) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership. Which has more risk & volatility, RGEN or TECH? Repligen has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Do analysts prefer RGEN or TECH? Repligen currently has a consensus target price of $169.45, indicating a potential upside of 42.51%. Bio-Techne has a consensus target price of $69.58, indicating a potential upside of 26.77%. Given Repligen's stronger consensus rating and higher possible upside, equities research analysts clearly believe Repligen is more favorable than Bio-Techne.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Repligen 0 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.67Bio-Techne 0 Sell rating(s) 6 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.62 Which has higher valuation and earnings, RGEN or TECH? Bio-Techne has higher revenue and earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRepligen$673.96M9.91-$25.51M-$0.25-475.64Bio-Techne$1.16B7.42$168.10M$0.8266.94 Is RGEN or TECH more profitable? Bio-Techne has a net margin of 10.89% compared to Repligen's net margin of -2.05%. Bio-Techne's return on equity of 13.17% beat Repligen's return on equity.Company Net Margins Return on Equity Return on Assets Repligen-2.05% 4.65% 3.26% Bio-Techne 10.89%13.17%10.17% Does the media favor RGEN or TECH? In the previous week, Repligen had 28 more articles in the media than Bio-Techne. MarketBeat recorded 45 mentions for Repligen and 17 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.18 beat Repligen's score of 0.51 indicating that Bio-Techne is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 13 Very Positive mention(s) 2 Positive mention(s) 14 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Bio-Techne 12 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in RGEN or TECH? 97.6% of Repligen shares are owned by institutional investors. Comparatively, 99.0% of Bio-Techne shares are owned by institutional investors. 1.2% of Repligen shares are owned by company insiders. Comparatively, 3.9% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryBio-Techne beats Repligen on 12 of the 17 factors compared between the two stocks. Get Repligen News Delivered to You Automatically Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RGEN vs. The Competition Export to ExcelMetricRepligenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.58B$3.00B$5.49B$9.52BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-475.6217.6228.7523.81Price / Sales9.91179.21372.2066.02Price / Cash37.6841.9535.4557.96Price / Book3.388.508.275.55Net Income-$25.51M-$55.06M$3.25B$259.20M7 Day Performance-2.32%-3.99%-3.72%-4.64%1 Month Performance-6.34%9.58%4.30%4.41%1 Year Performance-26.45%6.70%25.87%17.95% Repligen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RGENRepligen4.693 of 5 stars$118.91+1.6%$169.45+42.5%-28.2%$6.58B$673.96M-475.621,778Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionTECHBio-Techne4.8672 of 5 stars$50.27-3.4%$70.00+39.2%-33.3%$7.88B$1.16B61.313,100News CoveragePositive NewsUpcoming EarningsAAgilent Technologies4.7728 of 5 stars$112.12-1.6%$139.77+24.7%-20.5%$31.85B$6.51B27.6817,900News CoverageDHRDanaher4.9712 of 5 stars$188.23-1.0%$248.48+32.0%-29.8%$134.71B$23.88B36.5563,000Positive NewsTMOThermo Fisher Scientific4.9941 of 5 stars$405.15-2.3%$599.30+47.9%-25.6%$152.94B$42.88B23.76125,000Positive NewsAnalyst UpgradeBIIBBiogen4.8472 of 5 stars$122.68-1.8%$186.37+51.9%-37.4%$18.31B$9.82B12.117,605Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionUTHRUnited Therapeutics4.9631 of 5 stars$293.12+0.4%$383.08+30.7%-10.2%$13.17B$2.99B11.701,305Trending NewsEarnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionGap UpNBIXNeurocrine Biosciences4.687 of 5 stars$131.83-0.1%$163.87+24.3%-15.8%$13.05B$2.36B44.691,800Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionINCYIncyte4.7558 of 5 stars$67.38-0.7%$74.47+10.5%+17.3%$13.04B$4.24B210.572,617Trending NewsAnalyst ForecastEXELExelixis4.9365 of 5 stars$44.26-0.5%$45.28+2.3%+53.8%$12.07B$2.17B20.121,147Trending NewsEarnings ReportAnalyst ForecastOptions VolumeAnalyst RevisionBMRNBioMarin Pharmaceutical4.9771 of 5 stars$56.56-1.3%$93.78+65.8%-31.3%$10.85B$2.85B21.033,040News CoverageUpcoming Earnings Related Companies and Tools Related Companies Bio-Techne Alternatives Agilent Technologies Alternatives Danaher Alternatives Thermo Fisher Scientific Alternatives Biogen Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives Incyte Alternatives Exelixis Alternatives BioMarin Pharmaceutical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RGEN) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Repligen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RGEN Stock Alerts